atoms

Kazia Therapeutics

AU: KZA

AU$40m market cap

AU$1.03 last close

Kazia Therapeutics’ lead asset is paxalisib, a PI3K inhibitor licensed from Genentech that can cross the blood-brain barrier. It is entering a pivotal study for GBM and is being investigated for other brain cancers (DIPG and brain metastases). Kazia also has the legacy asset Cantrixil in Phase I for ovarian cancer.

Investment summary

Kazia is developing two anti-cancer compounds, paxalisib (GDC-0084) and Cantrixil. Paxalisib is a PI3K inhibitor, a well understood class with activity across a wide range of tumor types and multiple previously approved drugs. Paxalisib, unlike other drugs of this class can cross the blood brain barrier, opening the potential to treat cancers of the brain. It is in Phase II studies and will be entering the pivotal GBM AGILE study by the end of 2020.

Y/E Jun
Revenue (A$m)
EBITDA (A$m)
PBT (A$m)
EPS (c)
P/E (x)
P/CF (x)
2019A 1.6 (7.4) (7.4) (12.8) N/A N/A
2020A 1.1 (10.8) (10.8) (14.8) N/A N/A
2021E 1.4 (11.4) (11.4) (11.5) N/A N/A
2022E 1.5 (12.0) (12.0) (11.5) N/A N/A
Industry outlook

GBM is the most common primary cancer of the brain with 11,500 new cases reported in the US per year. There are currently very limited treatment options for GBM and the disease has a very low survival rate. Paxalisib is currently being developed for use in the adjuvant setting after initial resection and radiation treatment.

Last updated on 28/08/2020
Register to receive research on Kazia Therapeutics as it is published
Sector
Healthcare
Share price graph
Balance sheet
Forecast net debt (A$m) 3.8
Forecast gearing ratio (%) 182
Key management
Iain Ross Chairman
James Garner CEO

Content on Kazia Therapeutics